Program Type: Midwest CEPAC

Interventions of Interest For questions please contact [email protected].

Interventions of Interest For questions please contact [email protected].

Interventions of Interest For questions please contact [email protected]. Final Documents

Intervention of Interest For questions please contact [email protected]. View the Key Stakeholder List. Final Documents

Interventions of Interest For questions please contact [email protected]. View the Key Stakeholder List. Final Documents

Interventions of Interest The independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic therapies; suzetrigine has potential to be cost-saving due to avoided future cases of opioid use disorder. Final Documents For questions please contact [email protected]. View the Key Stakeholder List. ICER’s Chief Medical Officer David Rind, MD, […]

Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tafamidis, acoramidis, and vutrisiran when compared to no disease-specific therapy. Tafamidis and acoramidis would achieve common thresholds for cost-effectiveness if priced between $13,600 to $39,000 per year. Final Documents For questions please contact [email protected]. View […]